ANOTHER FEATHER IN THE CAP: BHU SCIENTISTS’ INNOVATION ON SARS COV-2 GETS GERMAN PATENT
Varanasi : Banaras Hindu University has got another feather in its cap with the granting of German patent to one of the milestone works of the varsity’s scientists. The work is about a breakthrough innovation in the fight against the SARS CoV-2 virus for a system to develop the Somnifericin Phyto molecule growth inhibitor. The patent has been granted by DPMA (German Patent and Trade Mark office) to the team of researchers comprising Prof. Parimal Das, Prashant Ranjan, Neha, Chandra Devi, Dr. Garima Jain, Prashasti Yadav, Dr. Chandana Basu Malick, and Dr. Bhagyalaxmi Mohapatra from the Centre for Genetic Disorders, Institute of Science.
The Somnifericin Phyto molecule growth inhibitor holds significant potential as an effective weapon to combat the SARS CoV-2 virus, which has posed a global threat to public health. This breakthrough development aims to provide a novel approach in containing the growth and proliferation of the virus, potentially leading to improved treatment options and preventive measures.
The innovative system, protected by the recently granted German patent, harnesses the power of the Somnifericin Phyto molecule to effectively inhibit the growth of the SARS CoV-2 virus. The interdisciplinary team of researchers has spent considerable time and effort in developing this cutting-edge solution, combining their expertise in virology, pharmacology, and molecular biology.
Prof. Parimal Das, Coordinator, Centre for Genetic Disorders, and one of the lead researchers, expressed excitement about the patent grant. He said “This German patent is a testament to our team’s dedication and commitment to finding innovative solutions to combat the SARS CoV-2 virus. We believe that the Somnifericin Phyto molecule growth inhibitor has the potential to make a significant impact in the ongoing battle against this global pandemic.”
The research team’s breakthrough discovery has opened up new possibilities for the development of antiviral therapies and preventive measures against the SARS CoV-2 virus. The granting of the German patent signifies a major milestone in their journey towards translating scientific advancements into practical solutions that can benefit individuals and communities worldwide.
With the patent protection in place, the research team is now poised to further explore the potential applications of the Somnifericin Phyto molecule growth inhibitor. They are actively seeking partnerships and collaborations with pharmaceutical companies, research institutions, and healthcare organizations to accelerate the development and eventual deployment of this groundbreaking innovation.
As the world continues to grapple with the challenges posed by the SARS CoV-2 virus, this German patent serves as a beacon of hope, signifying progress and the collective efforts of dedicated researchers. The team behind the Somnifericin Phyto molecule growth inhibitor remains committed to advancing their research and ultimately making a meaningful impact in the fight against this global health crisis.